BioSpace News Archive

Oxurion NV announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Astellas Pharma Inc. announced that The Lancet published detailed data from the Phase 3 SPOTLIGHT trial evaluating first-line treatment with zolbetuximab, an investigational first-in-class Claudin 18.2 targeted monoclonal antibody, plus mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

RELIEF THERAPEUTICS Holding SA reported its financial results for the full-year ended December 31, 2022 and provided a corporate update.

Hansa Biopharma AB will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.

Bio-Thera Solutions, Ltd. announced the company will present one poster concerning Phase 1 clinical results for BAT1006 at the 2023 American Association for Cancer Research Annual Meeting taking place April 14 - April 19, 2023 in Orlando, Florida.

Minghui Pharmaceutical, Inc. today announced positive top line results from its Phase 2 study evaluating MH004 Cream, the topical cream of a pan-JAK inhibitor, for treatment of adolescents and adults with mild-to-moderate atopic dermatitis (AD).

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to have received notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Ginkgo Bioworks and the Institut National de la Recherche Biomédicale today announced that they have entered into a Memorandum of Understanding (“MOU”) with the intent of developing and implementing new biosecurity capabilities in Democratic Republic of the Congo.

Curiteva pioneered and received clearance of the world’s first 3D printed, fully interconnected porous PEEK structure, utilizing internally developed Fused Filament Fabrication.